Reata Announces Clinical Trial Design for FALCON, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease

World News: . []

IRVING Texas Jan 03 2019 GLOBE NEWSWIRE -- Reata Pharmaceuticals Inc (Nasdaq: RETA a clinical-stage biopharmaceutical company today announced that it has completed a successful end-of-Phase 2 meeting with the United States Food and Drug Admini...

More news and information about Reata Pharmaceuticals, Inc.

Published By:

Globe Newswire: 21:01 GMT Thursday 3rd January 2019

Published: .

Search for other references to "reata" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us